Logo Prima Biomed

Welcome to the Newsroom

13 February 2017

Prima BioMed Receives ~A$860,000 Tax Credit Payment from French Government



SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”), is pleased to announce that its French subsidiary, Immutep S.A.S., has received €618,307 (approximately A$860,000) in payment of a research tax credit from the French state under the Crédit d’Impôt Recherche scheme. The cash payment was with respect to expenditure incurred by Immutep on European R&D activities in the 2015 calendar year, related to the Company’s LAG-3 programs.